Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec

News   Dec 17, 2012

 
Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec
 
 
 
 

RELATED ARTICLES

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

News

TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.

READ MORE

Shedding Light on How Tumors Become Resistant to Immunotherapy

News

Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.

READ MORE

Ingestible Drug-Delivery Materials May Improve Patient Treatment Compliance

News

Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE